🇺🇸 FDA
Patent

US 8853252

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61KA61K31/415A61P

Quick answer

US patent 8853252 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/415, A61P, A61P1/00, A61P1/16